Search Results - "Bidard, F"

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle by De Mattos-Arruda, L., Weigelt, B., Cortes, J., Won, H.H., Ng, C.K.Y., Nuciforo, P., Bidard, F.-C., Aura, C., Saura, C., Peg, V., Piscuoglio, S., Oliveira, M., Smolders, Y., Patel, P., Norton, L., Tabernero, J., Berger, M.F., Seoane, J., Reis-Filho, J.S.

“…Plasma-derived cell-free tumor DNA (ctDNA) constitutes a potential surrogate for tumor DNA obtained from tissue biopsies. We posit that massively parallel…”
Get full text

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group by Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J.D., Montagut, C., Normanno, N., Pantel, K., Pentheroudakis, G., Popat, S., Reis-Filho, J.S., Tie, J., Seoane, J., Tarazona, N., Yoshino, T., Turner, N.C.

“…Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. The European Society…”
Get full text

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients by Pierga, J.-Y., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Diéras, V., Rolland, E., Mignot, L., Mathiot, C., Bidard, F.-C.

“…Circulating tumor cells (CTCs) are a prognostic marker in metastatic breast cancer, but comparisons with serum tumor markers (CA 15-3, carcinoembryonic antigen…”
Get full text

Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study by Cabel, L., Riva, F., Servois, V., Livartowski, A., Daniel, C., Rampanou, A., Lantz, O., Romano, E., Milder, M., Buecher, B., Piperno-Neumann, S., Bernard, V., Baulande, S., Bieche, I., Pierga, J.Y., Proudhon, C., Bidard, F.-C.

“…Recent clinical results support the use of new immune checkpoint blockers (ICB), such as anti-PD-1 (e.g. nivolumab and pembrolizumab) and anti-PD-L1…”
Get full text

Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know? by Cabel, L, Proudhon, C, Mariani, P, Tzanis, D, Beinse, G, Bieche, I, Pierga, J.-Y, Bidard, F.-C

“…Abstract As a result of recent progress in detection techniques, circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) can now be accurately detected…”
Get full text

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer by Bidard, F.-C., Mathiot, C., Delaloge, S., Brain, E., Giachetti, S., de Cremoux, P., Marty, M., Pierga, J.-Y.

“…Circulation of cancer cells in the blood is a mandatory step for metastasis, but circulating tumor cells (CTC) have a low metastatic efficiency in preclinical…”
Get full text

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy by Bidard, F.-C., Mathiot, C., Degeorges, A., Etienne-Grimaldi, M.-C., Delva, R., Pivot, X., Veyret, C., Bergougnoux, L., de Cremoux, P., Milano, G., Pierga, J.-Y.

“…We investigated whether circulating tumor cells (CTCs) and circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy combined…”
Get full text

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer by Poumeaud, F., Morisseau, M., Cabel, L., Gonçalves, A., Rivier, C., Trédan, O., Volant, E., Frenel, J.-S., Ladoire, S., Jacot, W., Jamelot, M., Foka Tichoue, H., Patsouris, A., Teixeira, L., Bidard, F.-C., Loirat, D., Brunet, M., Levy, C., Bailleux, C., Cabarrou, B., Deleuze, A., Uwer, L., Deluche, E., Grellety, T., Franchet, C., Fiteni, F., Bischoff, H., Vion, R., Pagliuca, M., Verret, B., Bécourt, S., Reverdy, T., de Nonneville, A., Dalenc, F.

“…Background Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates (ADCs):…”
Get full text

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer by Van Baelen, K, Geukens, T, Maetens, M, Tjan-Heijnen, V, Lord, C J, Linn, S, Bidard, F-C, Richard, F, Yang, W W, Steele, R E, Pettitt, S J, Van Ongeval, C, De Schepper, M, Isnaldi, E, Nevelsteen, I, Smeets, A, Punie, K, Voorwerk, L, Wildiers, H, Floris, G, Vincent-Salomon, A, Derksen, P W B, Neven, P, Senkus, E, Sawyer, E, Kok, M, Desmedt, C

“…Invasive lobular breast cancer (ILC) is the second most common type of breast cancer after invasive breast cancer of no special type (NST), representing up to…”
Get full text

Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer by Ligthart, S.T., Bidard, F.-C., Decraene, C., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Viens, P., Pierga, J.-Y., Terstappen, L.W.M.M.

“…Circulating tumor cells (CTCs) can provide the basis for a liquid biopsy and may guide the use of targeted therapies. We report on unbiased quantification of…”
Get full text

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial by Bidard, F.C., Huguet, F., Louvet, C., Mineur, L., Bouché, O., Chibaudel, B., Artru, P., Desseigne, F., Bachet, J.B., Mathiot, C., Pierga, J.Y., Hammel, P.

“…Pancreatic carcinoma is one of the leading causes of cancer-related mortality. At the time of diagnosis, 30% of patients present with a locally advanced…”
Get full text

Circulating tumor DNA detection in hepatocellular carcinoma by Cabel, L., Proudhon, C., Buecher, B., Pierga, J.-Y., Bidard, F.-C.

Get full text

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) by Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., Mousseau, M., Dauba, J., Del Piano, F., Desmoulins, I., Coussy, F., Madranges, N., Grenier, J., Bidard, F.C., Proudhon, C., MacGrogan, G., Orsini, C., Pulido, M., Gonçalves, A.

“…Several expression array studies identified molecular apocrine breast cancer (BC) as a subtype that expresses androgen receptor (AR) but not estrogen receptor…”
Get full text

Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells by Bidard, F.-C., Vincent-Salomon, A., Sigal-Zafrani, B., Diéras, V., Mathiot, C., Mignot, L., Thiery, J.-P., Sastre-Garau, X., Pierga, J.-Y.

“…At metastatic relapse, detection of circulating tumor cells (CTC) in peripheral blood is predictive of poor survival of breast cancer patients. Detection of…”
Get full text

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial by Pierga, J.-Y., Bidard, F.-C., Cropet, C., Tresca, P., Dalenc, F., Romieu, G., Campone, M., Mahier Aït-Oukhatar, C., Le Rhun, E., Gonçalves, A., Leheurteur, M., Dômont, J., Gutierrez, M., Curé, H., Ferrero, J.-M., Labbe-Devilliers, C., Bachelot, T.

“…Decrease of circulating tumor cells (CTC) during treatment is an independent prognostic factor in metastatic breast cancer (MBC). We specifically evaluated the…”
Get full text

Circulating tumor cell count and thrombosis in metastatic breast cancer by Beinse, G., Berger, F., Cottu, P., Dujaric, M.‐E., Kriegel, I., Guilhaume, M.‐N., Diéras, V., Cabel, L., Pierga, J.‐Y., Bidard, F.‐C.

“…Essentials Tumor cells circulating in blood (CTC) may favor thrombotic events in cancer patients. We assessed the impact of CTC on the risk of thrombosis in…”
Get full text

Survival of breast cancer patients with meningeal carcinomatosis by Gauthier, H., Guilhaume, M.N., Bidard, F.C., Pierga, J.Y., Girre, V., Cottu, P.H., Laurence, V., Livartowski, A., Mignot, L., Diéras, V.

“…Breast cancer is the leading nonhematologic cause of meningeal carcinomatosis (MC). The aim of this study was to report the outcome of patients diagnosed with…”
Get full text

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program by Bello Roufai, D., Gonçalves, A., De La Motte Rouge, T., Akla, S., Blonz, C., Grenier, J., Gligorov, J., Saghatchian, M., Bailleux, C., Simon, H., Desmoulins, I., Tharin, Z., Renaud, E., Bertho, M., Benderra, M-A, Delaloge, S., Robert, L., Cottu, P., Pierga, J. Y., Loirat, D., Bertucci, A., Renouf, B., Bidard, F. C., Lerebours, F.

Get full text

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program by Bello Roufai, D., Gonçalves, A., De La Motte Rouge, T., Akla, S., Blonz, C., Grenier, J., Gligorov, J., Saghatchian, M., Bailleux, C., Simon, H., Desmoulins, I., Tharin, Z., Renaud, E., Bertho, M., Benderra, M-A, Delaloge, S., Robert, L., Cottu, P., Pierga, J. Y., Loirat, D., Bertucci, A., Renouf, B., Bidard, F. C., Lerebours, F.

“…SOLAR-1 and BYLieve trials documented the efficacy of the PI3K-inhibitor alpelisib in pre-treated PIK3CA -mutant, hormone receptor-positive, HER2-negative…”
Get full text

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab by Pierga, J.-Y., Bidard, F.-C., Autret, A., Petit, T., Andre, F., Dalenc, F., Levy, C., Ferrero, J.-M., Romieu, G., Bonneterre, J., Lerebours, F., Bachelot, T., Kerbrat, P., Campone, M., Eymard, J.-C., Mouret-Reynier, M.-A., Gligorov, J., Hardy-Bessard, A.-C., Lortholary, A., Soulie, P., Boher, J.-M., Proudhon, C., Charafe-Jaufret, E., Lemonnier, J., Bertucci, F., Viens, P.

“…We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective…”
Get full text